In fact, the presence of a cutoff with high levels of AFP restricts the use of therapy to a specific subset of patients with HCC; moreover, the improvement of OS seems to be marginal with a median OS of 1.2 months [31]. The gene discussed is AFP; the disease is hepatocellular carcinoma.